AbbVie 2013 Annual Report Download - page 108

Download and view the complete annual report

Please find page 108 of the 2013 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 176

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176

PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Incorporated herein by reference are ‘‘Information Concerning Director Nominees,’’ ‘‘The Board
of Directors and its Committees—Committees of the Board of Directors,’’ ‘‘Section 16(a) Beneficial
Ownership Reporting Compliance,’’ and ‘‘Procedure for Recommendation and Nomination of Directors
and Transaction of Business at Annual Meeting’’ to be included in the 2014 AbbVie Inc. Proxy
Statement. The 2014 Proxy Statement will be filed on or about March 24, 2014. Also incorporated
herein by reference is the text found under the caption, ‘‘Executive Officers of the Registrant’’ on
pages 29 and 30 hereof.
AbbVie’s code of business conduct requires all its business activities to be conducted in compliance
with laws, regulations, and ethical principles and values. All directors, officers, and employees of
AbbVie are required to read, understand, and abide by the requirements of the code of business
conduct applicable to them. AbbVie’s code of business conduct is available in the corporate governance
section of AbbVie’s investor relations website at www.abbvieinvestor.com.
Any waiver of the code of business conduct for directors or executive officers may be made only by
AbbVie’s audit committee. AbbVie will disclose any amendment to, or waiver from, a provision of the
code of conduct for the principal executive officer, principal financial officer, principal accounting
officer or controller, or persons performing similar functions, on its website within four business days
following the date of the amendment or waiver. In addition, AbbVie will disclose any waiver from the
code of business conduct for the other executive officers and for directors on the website.
AbbVie has a chief ethics and compliance officer who reports to the chief executive officer and to
the public policy committee. The chief ethics and compliance officer is responsible for overseeing,
administering, and monitoring AbbVie’s compliance program.
ITEM 11. EXECUTIVE COMPENSATION
The material to be included in the 2014 Proxy Statement under the headings ‘‘Director
Compensation,’’ ‘‘Executive Compensation,’’ and ‘‘Compensation Committee Report’’ is incorporated
herein by reference. The 2014 Proxy Statement will be filed on or about March 24, 2014.
104